CA
NZ
UK
AU
IND
US
The preliminary figures showed revenue of €300.1 million for the first half of the year, alongside an adjusted EBITDA loss of €42.7 million. Reporting an EBITDA loss, rather than positive earnings, represents a significant deterioration for a company of Evotec's scale and maturity in …
The scale of today's decline is directly tied to the ownership structure embedded in the merger: existing Matinas stockholders will retain only roughly 9% ownership in the reorganized company. A retained stake this modest signals that the substantial majority of the combined company's future …
Under the terms of the sale, Matinas will receive $4.0 million in upfront cash, a relatively modest sum that reflects the transaction structure's heavier reliance on contingent, milestone-based consideration rather than a larger immediate payment. This structure is a common approach in biotech asset …
The long-term extension data, drawn from 34 patients with up to 15.9 months of drug exposure, showed a 92% reduction in treated bleeding events, a substantial improvement speaking to sutacimig's potential to meaningfully reduce the bleeding burden faced by patients with this rare and …
The Phase 2/3 designation itself reflects the transitional nature of sutacimig's current development stage: the company has completed a Phase 2 long-term extension study while simultaneously planning its registration-directed Phase 3 trial, a designation that captures both the maturity of the existing dataset and …
Private placements of this size are relatively uncommon for early clinical-stage biotech companies, and the involvement of Hansoh Pharma as a lead investor carries particular significance given that Hansoh is also the company that originally licensed AVR-001, Avere's lead drug candidate, to the business. …
Today's favorable reaction suggests that investors may have been more focused on the certainty and finalization of funding than on the incremental dilution associated with the raise. For small-cap biotech companies operating with limited cash runway, removing uncertainty about near-term financing availability can itself …
At the center of the deal is Utebzi, Spero's approved oral antibiotic currently partnered with GSK. Under the arrangement, Spero is trading away its rights to future milestone payments and net sales royalties tied to Utebzi in exchange for the $105 million in upfront …
At the center of the agreement is SP001, a Phase 2-ready anti-CD40L monoclonal antibody that Spero is in-licensing from Innovent. CD40L is a protein involved in immune cell signaling that plays a central role in numerous autoimmune and inflammatory conditions, and antibodies targeting this …
AVR-001's defining engineering feature is its approximately 100-hour half-life, which enables once-weekly oral administration. Achieving this kind of metabolic stability in a cyclic peptide is a notable technical accomplishment, as peptides have historically struggled to achieve the durability needed for infrequent oral dosing given …
Please wait processing your request...